Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRUISECONTROL2: Continued vs. Interrupted NOAC in Device Surgery
NCT01675076Phase 3Completed
- Sponsor
- University of Ottawa Heart Institute
- Start
- Jan 2013
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, single-blind trial of dabigatran, rivaroxaban and apixaban in Atrial fibrillation (AFib) and atrial flutter (AFL), sponsored by University of Ottawa Heart Institute. Started Jan 2013; status: completed.
02
Drugs
dabigatranrivaroxabanapixaban
03
Conditions
Atrial fibrillation (AFib)atrial flutter (AFL)
Beyond the preview
Go deeper on NCT01675076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01675076.